Holbrook E. Kohrt

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014 · 5.3K citations

Medicine, Immunology, Oncology +16

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Paul Nghiem, Shailender Bhatia, Evan J. Lipson et al. · New England Journal of Medicine · 2016 · 1.2K citations · Full text

Medicine, Dermatology, Oncology +17

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

Mark P. Chao, Ash A. Alizadeh, Chad Tang et al. · Cell · 2010 · 1.1K citations · Full text

Medicine, Immunology, Oncology +14

Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions

Alexander Filatenkov, Jeanette Baker, Antonia M.S. Mueller et al. · Clinical Cancer Research · 2015 · 480 citations · Full text

Medicine, Immunology, Oncology +17

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

Idit Sagiv-Barfi, Holbrook E. Kohrt, Debra K. Czerwinski et al. · Proceedings of the National Academy of Sciences · 2015 · 446 citations · Full text

Medicine, Oncology, Pharmacology +17